H.R. 1’s limits on Medicaid eligibility for certain immigrants -- a provision the National Association of Medicaid Directors head worried hasn't been publicly discussed enough and that beneficiary ...

A new benchmark system designed to measure and track the structural fragility of the nation’s drug supply chain shows more than 550 million prescriptions were filled in 2023 for medicines with high or ...

HHS will begin developing a standardized format for health plans to disclose their negotiated prescription drug prices next month, CMS official Peter Nelson announced Monday (Oct. 5), with CMS ...

As several pharmacy benefit manager reform bills move through Congress, the top PBM lobby is leveraging a new government report to refute criticism that PBM-owned pharmacies under Medicare Part D ...

Amid the Trump administration’s push to expand access to psychedelic drug therapies, FDA released a request for information Monday (Oct. 5) outlining for the first time how sponsors could safely ...

As HHS increasingly integrates AI into internal systems and government health programs, a pair of bipartisan senators are reintroducing the Transparent Automated Governance Act that would require the ...

A new AARP report analyzes the tactics AstraZeneca used to prevent lower-cost alternatives to its blockbuster inhaler Symbicort from entering the market when the brand drug’s exclusivity period was ...

FDA’s push to find new members for its advisory committees could reshape the agency’s key panel that provides recommendations on vaccine approvals, adding up to 10 new members.

The much-anticipated final rule updating requirements for insurers and group health plans to publish negotiated prices has cleared the White House Office of Management and Budget.

Congress should reauthorize the Older Americans Act's (OAA) reporting requirements, program integrity safeguards and accountability measures, HHS Secretary Robert F. Kennedy Jr. said in a recent ...

Eli Lilly is moving forward with plans to ask FDA to approve its latest experimental weight-loss drug, retatrutide, as a biologic after the GLP-1 showed substantial weight loss in patients with ...